|
|
|
|
|
 |
News and Press Releases |
 |
BioIVT Acquires Cypex, a Leading Manufacturer of Drug-Metabolizing Enzymes
Westbury, NY – August 8, 2022 – BioIVT, a leading provider of
biospecimens, research models and services for drug and diagnostic
development, today announced that it has acquired Cypex, a renowned
manufacturer of recombinant xenobiotic metabolizing enzymes, based in
Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range
of proteins involved in drug metabolism.
More info >> |
|
 |
White Papers |
 |
|
Maximize the ROI of Your Post-Approval Research
Bioclinica
Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment.
Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >> |
|
|
